Key Takeaways
- dsm-firmenich has filed a patent infringement lawsuit in China over unauthorized sclareol production.
- The company claims multiple Chinese entities have violated its 2009 patent regarding biotech methods for sclareol production.
- dsm-firmenich seeks a court order to stop the infringement and secure compensation for its losses.
Legal Action Initiated Over Sclareol Patent Infringement
dsm-firmenich, a prominent manufacturer of nutrients, flavors, and fragrances, has launched a patent infringement lawsuit in the Xiong’An New District Court in Hebei Province, China. The action involves several Chinese entities, including a sclareol producer and a research institute, accused of unlawfully using dsm-firmenich’s patented methods for producing sclareol through biotechnology.
Sclareol, a fragrant compound derived from clary sage (Salvia sclarea L.), plays a crucial role as an intermediate in the creation of amber fragrance ingredients, notably Ambrox®. In 2009, dsm-firmenich secured a patent for a biotechnological approach to sclareol production, cementing its intellectual property rights in this area.
In their legal petition, dsm-firmenich has requested that the court order the defendants to halt their unauthorized activities and compensate the company for the damages incurred from this infringement. The company’s Executive Vice President for Perfumery & Beauty Ingredients, Amaury Roquette, emphasized the organization’s strong intellectual property portfolio and its commitment to protecting its innovations.
Roquette stated, “As a global leader in perfumery and beauty innovation, dsm-firmenich holds a robust portfolio of proprietary technologies. Our well-established intellectual property (IP) position, including patent rights and deep know-how on sclareol and related derivatives, enables us to ensure that our customers continue to benefit from our innovation, quality, and expertise in amber-type fragrance ingredients.”
He further added that due to the robustness of their IP position concerning sclareol and its derivatives, dsm-firmenich is dedicated to pursuing all necessary legal avenues to uphold the company’s rights and protect its substantial investments in innovation, as well as its clients, on a global scale. The outcome of this litigation could have significant implications not only for dsm-firmenich but also for the broader biotechnology and fragrance industries.
The content above is a summary. For more details, see the source article.